Wells Fargo & Company MN Sells 67,546 Shares of Grifols, S.A. (NASDAQ:GRFS)

Wells Fargo & Company MN cut its stake in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 9.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 625,453 shares of the biotechnology company's stock after selling 67,546 shares during the period. Wells Fargo & Company MN owned approximately 0.09% of Grifols worth $4,653,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in GRFS. HighTower Advisors LLC lifted its position in Grifols by 12.5% in the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company's stock valued at $123,000 after purchasing an additional 1,546 shares during the period. Stifel Financial Corp purchased a new position in Grifols in the third quarter worth $1,043,000. Jane Street Group LLC purchased a new stake in shares of Grifols during the 3rd quarter worth $363,000. Barclays PLC increased its holdings in shares of Grifols by 381.2% in the 3rd quarter. Barclays PLC now owns 592,552 shares of the biotechnology company's stock valued at $5,261,000 after purchasing an additional 469,401 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Grifols by 56.1% in the third quarter. Geode Capital Management LLC now owns 110,532 shares of the biotechnology company's stock valued at $982,000 after purchasing an additional 39,733 shares during the period.

Grifols Price Performance

Shares of NASDAQ:GRFS traded up $0.02 on Friday, hitting $7.20. The company had a trading volume of 667,362 shares, compared to its average volume of 1,205,551. The business has a 50 day moving average of $7.48 and a 200 day moving average of $7.77. Grifols, S.A. has a 52-week low of $5.79 and a 52-week high of $9.96. The company has a market cap of $4.95 billion, a PE ratio of 6.15 and a beta of 0.41. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11.

Analyst Ratings Changes

Separately, Morgan Stanley initiated coverage on shares of Grifols in a research report on Wednesday, February 12th. They set an "overweight" rating for the company.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.